Akebia, Otsuka collaborate on drug to treat chronic kidney disease-induced anemia
Akebia Therapeutics Inc. and Otsuka Pharmaceutical Co. Ltd. recently entered a collaboration and license agreement in the U.S. for vadadustat, an oral hypoxia-inducible factor stabilizer in development for the treatment of anemia associated with chronic kidney disease Read More »
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
                
                
                
                
                
          Alerts Sign-up